Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company’s lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for the treatment of Alzheimer’s disease and has completed phase 2 study for the treatment of Huntington’s disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; Pepinemab in combination with Nivolumab completed phase 2 study for melanoma; and trastuzumab and dendritic cell vaccines in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children’s Hospital of Philadelphia; Emory University; Huntington Study Group; Catalent Pharma Solutions, LLC; and Surface Oncology, Inc. The company was incorporated in 2001 and is headquartered in Rochester, New York.
Metrics to compare | VCNX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVCNXPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.1x | −0.6x | −0.5x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | −0.5x | 1.7x | 2.6x | |
Price / LTM Sales | 3.7x | 10.8x | 3.1x | |
Upside (Analyst Target) | - | 210.1% | 51.1% | |
Fair Value Upside | Unlock | 20.7% | 8.9% | Unlock |